Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 470 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.5B 399 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AO Atlas Oncology PartnersCompany profile Delivers uplifting and responsive cancer care during and beyond treatment Delivers uplifting and responsive cancer care during and beyond treatment | $28M | Series A | Biotech, Healthtech | United States | Investors | |
| 4B 4Moving BiotechCompany profile Clinical-stage development of a locally delivered GLP-1 therapy for inflammatory knee osteoarthritis. Clinical-stage development of a locally delivered GLP-1 therapy for inflammatory knee osteoarthritis. | €12M | Debt and equity financingUndisclosed | Biotech | France | Investors Undisclosed | |
| A ArrayPatchCompany profile Develops microneedle-based therapeutics for treatment of nail fungus and other diseases Develops microneedle-based therapeutics for treatment of nail fungus and other diseases | €3M | Seed | Biotech, Healthtech | Ireland | Investors | |
| IB Developing a next-generation pertussis vaccine candidate BPZE1 | $115M | Series B | Biotech | United States | Investors | |
| PT Pandorum TechnologiesCompany profile Develops tunable, regenerative exosome therapies for tissue health, disease, and degeneration Develops tunable, regenerative exosome therapies for tissue health, disease, and degeneration | $18M | Series B | Biotech | India | Investors | |
| G GaluxCompany profile Develops AI-driven protein design platform for de novo antibody and drug discovery Develops AI-driven protein design platform for de novo antibody and drug discovery | $29M | Series B | Biotech | South Korea | Investors | |
| TA Third Arc BioCompany profile Develops novel multifunctional antibodies for oncology and immunology & inflammation indications Develops novel multifunctional antibodies for oncology and immunology & inflammation indications | $52M | Series A+Series A | Biotech | United States | Investors | |
| ES Evergreen SelectCompany profile Produces cultivated beef for integration into existing food-production systems. Produces cultivated beef for integration into existing food-production systems. | $6M | Undisclosed | Biotech, Foodtech | United States | Investors | |
| QS Develops quantum-based platform for real-time cell analysis | €4M | Seed | Biotech | Netherlands | Investors | |
| b Physician-led preventive care platform using AI for early cancer detection | $4M | Seed | Biotech, Healthtech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.